
Seer, Inc. — Investor Relations & Filings
Seer, Inc. is a life sciences company that develops and commercializes products to advance proteomics research. The company's core offering is the Proteograph Product Suite, an integrated platform designed to provide deep, unbiased, and large-scale access to the proteome. Utilizing proprietary engineered nanoparticles, Seer's technology enables researchers to analyze complex biological samples with high throughput, speed, and reproducibility. This approach facilitates the comprehensive detection of proteins, including those at low abundance that are critical for understanding disease and health states. The platform is complemented by the Proteograph Analysis Suite, a software solution for data analysis and biomarker discovery. Seer aims to empower the scientific community with tools to overcome technological barriers in proteomics, accelerating insights in precision medicine and human biology.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-K/A - Seer, Inc. (0001726445) (Filer) | 2026-04-30 | English | |
| DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-29 | English | |
| DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-24 | English | |
| 8-K - Seer, Inc. (0001726445) (Filer) | 2026-04-13 | English | |
| DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-13 | English | |
| 10-K - SEER, INC. (0001726445) (Filer) | 2026-03-02 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
12 filings
| |||||
| 39212809 | 10-K/A - Seer, Inc. (0001726445) (Filer) | 2026-04-30 | English | ||
| 38584983 | DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-29 | English | ||
| 36141962 | DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-24 | English | ||
| 34439529 | 8-K - Seer, Inc. (0001726445) (Filer) | 2026-04-13 | English | ||
| 34439493 | DFAN14A - Seer, Inc. (0001726445) (Subject) | 2026-04-13 | English | ||
| 32897348 | 10-K - SEER, INC. (0001726445) (Filer) | 2026-03-02 | English | ||
| 32897347 | 8-K - SEER, INC. (0001726445) (Filer) | 2026-02-26 | English | ||
| 32897346 | 8-K - SEER, INC. (0001726445) (Filer) | 2026-02-26 | English | ||
| 32897344 | 4 - SEER, INC. (0001726445) (Filer) | 2026-02-19 | English | ||
| 32897345 | 4 - SEER, INC. (0001726445) (Filer) | 2026-02-19 | English | ||
| 31497902 | 4 Filing | 2026-02-05 | English | ||
| 31497881 | 4 Filing | 2026-02-05 | English | ||
|
2025
3 filings
| |||||
| 13086780 | 8-K | 2025-12-12 | English | ||
| 13086781 | Director's Dealing 2025 | 2025-12-12 | English | ||
| 13086784 | Director's Dealing 2025 | 2025-12-12 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
CALIWAY BIOPHARMACEUTICALS CO., LTD.
Develops small-molecule therapeutics for medical aesthetics…
|
6919 | TW | Professional, scientific and te… |
|
CALIX LIMITED
Develops industrial carbon capture and sustainable mineral …
|
CXL | AU | Professional, scientific and te… |
|
CAMBIUM BIO LIMITED
Clinical-stage developer of cellular therapies for ophthalm…
|
CMB | AU | Professional, scientific and te… |
|
CAMBRIDGE COGNITION HOLDINGS PLC
Develops digital solutions and a platform for CNS clinical …
|
COG | GB | Professional, scientific and te… |
|
CanBas Co.,Ltd.
A clinical-stage biopharmaceutical company developing novel…
|
4575 | JP | Professional, scientific and te… |
|
Captor Therapeutics S.A.
Develops Targeted Protein Degradation therapies for cancer …
|
CTX | PL | Professional, scientific and te… |
|
Cardiff Oncology, Inc.
A clinical-stage biotech developing cancer therapies that i…
|
CRDF | US | Professional, scientific and te… |
|
Cardio Diagnostics Holdings, Inc.
Develops AI-powered epigenetic and genetic tests for early …
|
CDIO | US | Professional, scientific and te… |
|
Cardiol Therapeutics Inc.
Clinical-stage company developing anti-inflammatory therapi…
|
CRDL | CA | Professional, scientific and te… |
|
CASSAVA SCIENCES INC
Clinical-stage biotech developing treatments for Central Ne…
|
SAVA | US | Professional, scientific and te… |
Seer, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34036/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34036 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34036 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34036 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34036}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Seer, Inc. (id: 34036)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.